Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

ation compliance by subjects, consistent trends in favor of CPP-109 over placebo were observed after the post-hoc analyses with respect to both primary and secondary efficacy endpoints. When corrected for poor medication compliance, the following favorable outcome trends were observed: (i) the log10 benzoylecgonine (the major metabolite of cocaine) levels measured in urine collected from subjects were consistently lower in the CPP-109 treatment group during the 12 week treatment period, generally indicating a reduction of cocaine use; and (ii) in those subjects who were compliant with study medication, the differences between CPP-109 and placebo were amplified, which suggest that CPP-109 may facilitate abstinence, reduce overall cocaine use as measured by urine benzoylecgonine levels (an objective measure of daily cocaine usage), and reduce cocaine usage days (an objective measure of dependence severity).

Consistent with previous published addiction trials, the protocol in the Company's cocaine trial assessed subjects' medication compliance based on self reporting and on counting the unused medication returned by subjects. Based on that methodology, the Company had an 85% compliance level. However, after post-hoc testing of urine samples from many of the trial's subjects, the Company has concluded that less than 40% of the trial subjects were compliant taking their medication. As a practical matter, the low medication compliance effectively reduced the power of the study because not all subjects in the treatment group were actually treated. However, analyses of subject responses, corrected for poor compliance, makes the response ratios observed in the Company's trial more consistent with the results reported by Dr. Jonathan Brodie et al. in a double-blind, placebo-controlled, 103-patient Phase II trial evaluating vigabatrin for the treatment of cocaine addiction (the results of which were recently published on-line in The American Journal of P
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... WASHINGTON , April 20, 2015  In ... nation,s healthcare markets, the FTC announced that Cardinal ... it illegally monopolized 25 local markets for the ... hospitals and clinics to pay inflated prices for ... to pay $26.8 million of ill-gotten gains and ...
(Date:4/20/2015)... April 20, 2015  Purdue Pharma, a leading ... Butcher has joined the company as Senior ... will have responsibility for all of Purdue,s efforts ... products that would benefit from our patient-focused commercial ... leader," said Purdue President & CEO Mark ...
(Date:4/20/2015)... YORK , April 20, 2015 ... pump market will continue to be robust; the ... incidence of diabetes, expanding global markets, new product ... there are relatively steady market inhibitors, such as ... an increasing competitive environment. The healthcare market research ...
Breaking Medicine Technology:Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3
... TARRYTOWN, N.Y., Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... the 17th Annual NewsMakers in the Biotech Industry Conference ... for 9:00 a.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
... Oct. 15 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that ... Stock Market indicating that it has regained compliance ... Listed Securities ("MVLS") requirement for continued listing on ...
Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
(Date:4/20/2015)... 1% for the Planet , one ... that Kate Williams, the network’s Director of Partnerships, will step ... Williams has been part of 1% for the Planet since ... of the Northern Forest Canoe Trail, a 1% for the ... the stewardship of and advocacy for the outdoors, a commitment ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
(Date:4/20/2015)... New York (PRWEB) April 20, 2015 ... Centers for Medicare & Medicaid Services introduced their new ... HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) ... survey asks patients about their experiences during a recent ... results from July 1, 2013 through June 30, 2014 ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Insuranceautoquote.info has ... find affordable car insurance quotes online . , ... for the best results. Clients should always compare online ... be done on a single website: . http://insuranceautoquote.info ... The questionnaire can be completed in a few minutes ...
Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
... BOSTON, Sept. 15 The 13th Annual ... (HFSA) today featured a discussion titled "Cardiovascular Disease in ... Chen, Director, Stress Echocardiography Program and Program for Cardiac ... Dr. Chen,s presentation highlights the increased risk of heart ...
... , , , ... HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... use of Nexavar((R)) (sorafenib) tablets across tumor types - as ... will be presented at the joint 15th European CanCer Organisation ...
... CRANBURY, N.J., Sept. 15 Palatin Technologies, Inc. ... on clinical trial results with PL-3994, its product for heart ... Meeting of the Heart Failure Society of America in Boston. ... of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive ...
... , , , ... abstract artist Susan Olmetti , one must only step ... step into the company of unconventional characters housed in an outlying charismatic ... mid-1800s and currently inhabited by more than 75 locally owned, independent businesses ...
... ALEXANDRIA, Va., Sept. 15 For overweight men ... cholesterol, high blood pressure, high blood sugar/glucose, poor diet and ... efforts to lose weight, according to Building Healthier America, a ... overweight and obesity in the U.S. , , ...
... , , , CAPE ... experiencing growth across a range of sectors. However, the drive ... medical imaging devices. , , (Logo: ... Frost & Sullivan ( http://www.medicaldevices.frost.com ), Overview ...
Cached Medicine News:Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 2Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 2Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 4Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 5Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 6Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 2Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 3Health News:Wine Reception Mixing up one Part Abstract Artist Susan Olmetti, one Part Chicago House Fundraiser, and one Part SIR Spa 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 3Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 2Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 3
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
96-well Silicone Compression Mat, Bulk...
Silicone Compression Mat, Bulk...
96-well Silicone Expansion Mat, Bulk...
Medicine Products: